Pancreatic Cancer News
Halozyme Therapeutics announced that the phase 3 HALO-301 study of PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreatic cancer has failed to meet the primary end point of overall survival.
Exceeding tolerances of healthy organs-at-risk as a result of daily anatomical deformations is a concern for patients with LAPC treated with SBRT.
Patients who had tumors measuring 1.5 cm to 2 cm were at double the risk for lymph node metastasis.
As cancer treatments become more complex, tumor boards can help simplify options.
Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings.
Risks for pancreatitis, pancreatic cancer higher in Korean patients with newly diagnosed T2DM.
Pancreatic ductal adenocarcinoma is characterized by a tumor microenvironment that inhibits immune signaling.
Continuous increase in risk of pancreatic cancer with elevating fasting glucose, even within normal range.
Cyst classifier test is based on clinical and imaging features, genetic and biochemical markers.
Boston Biomedical has announced that the CanStem111P study investigating napabucasin in patients with metastatic pancreatic cancer will be discontinued due to futility.
The rate of grade 3/4 adverse events was higher for patients with resected pancreatic adenocarcinoma treated with adjuvant mFOLFIRINOX versus gemcitabine.
The median duration of response to olaparib in these patients with metastatic pancreatic cancer was more than 2 years.
Many patients with noncurable pancreatic adenocarcinoma do not have a specialized cancer consultation and most do not receive cancer-directed therapy.
Regions of tumor and normal tissue on FFPE tissue specimens obtained from the NCI SEER-linked Virtual Tissue Repository were annotated by a pathologist.
Olaparib maintenance therapy improved PFS in patients with metastatic pancreatic adenocarcinoma characterized by a deleterious BRCA1/2 mutation.
Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.
Study results suggest a new combination regimen could become the standard of care for some patients.
Researchers are seeking to assess the initial safety and efficacy of LUM015 imaging of colorectal, pancreatic, and esophageal cancers using the LUM 2.6 imaging device.
Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.
The local delivery of cancer medications, via microparticles, is being explored in pancreatic cancer.